You are here

kidney cancer

Exelixis Gets the Patients Eventually

Motley Fool

Mon, 08/6/18 - 11:47 pm

renal cell carcinoma

Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action

Fierce Pharma

Fri, 08/3/18 - 11:33 am

Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer

Fierce Pharma

Mon, 04/16/18 - 11:36 pm

Bristol-Myers Squibb

Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure

Fierce Pharma

Thu, 04/12/18 - 11:46 am

renal cell carcinoma

Novartis offloads failed cancer drug to Oncology Venture

Fierce Biotech

Wed, 04/11/18 - 09:32 am

Oncology Venture

Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data

Endpoints

Mon, 02/5/18 - 07:07 pm

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

GoinPharma

Wed, 01/17/18 - 10:05 am

Bristol-Myers Squibb

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Fierce Pharma

Fri, 01/12/18 - 06:39 pm

Pfizer defends kidney-cancer position with Bavencio 'breakthrough'

Fierce Pharma

Wed, 01/3/18 - 10:58 am

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Reuters

Wed, 12/20/17 - 09:39 am

Cancer Space Update: Label Expansion for Three Major Drugs

Yahoo/Zacks.com

Fri, 11/17/17 - 11:45 am

follicular lymphoma

Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer

Fierce Pharma

Wed, 11/1/17 - 11:04 am

Bristol-Myers Squibb

Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales

Fierce Pharma

Thu, 09/21/17 - 10:02 pm

Ipsen focuses on oncology to keep growing

GoInPharma

Mon, 09/18/17 - 09:24 am

Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale

Motley Fool

Thu, 09/14/17 - 06:56 pm

Bristol-Myers Squibb

Opdivo combo shows early survival benefit in kidney cancer

BioPharma Dive

Fri, 09/8/17 - 09:34 am

Bristol-Myers Squibb

Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer

Xconomy

Wed, 08/16/17 - 10:13 am

Bristol-Myers Squibb

Aveo soars as long-beleaguered cancer drug nears approval

Fierce Biotech

Sat, 06/24/17 - 09:23 am

Acceleron dumps dalantercept after kidney cancer trial fail

Fierce Biotech

Tue, 06/13/17 - 11:57 am

clinical trials

Roche says Phase II trial supports twin treatment for kidney cancer

Yahoo/Reuters

Sat, 02/18/17 - 02:35 pm

Pages